View Older Stories
-
Nuvation Bio Inc (NUVB) PT Raised to $13 at Truist Securities
-
Nuvation Bio Inc (NUVB) PT Raised to $12 at Jones Trading
-
Nuvation Bio Inc (NUVB) PT Lowered to $17 at H.C. Wainwright
-
Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens: Top-Line Growing
-
Nuvation Bio reports $24.7 million in revenue for cancer drug IBTROZI
-
Nuvation Bio partners with Eisai for taletrectinib in Europe
-
UBS Starts Nuvation Bio Inc (NUVB) at Neutral
-
Why Jefferies sees these stocks as standout biotech plays in 2026
-
Nuvation Bio Inc (NUVB) PT Raised to $18 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
Nuvation Bio discontinues NUV-1511 drug development program
-
Truist Securities Starts Nuvation Bio Inc (NUVB) at Buy
-
Nuvation Bio Inc (NUVB) PT Raised to $10 at Citizens on Safusidenib Plans
-
B.Riley Starts Nuvation Bio Inc (NUVB) at Buy
-
Nuvation Bio Inc (NUVB) PT Raised to $8 at Citizens: Launch Trajectory Impressive
-
Nuvation Bio Inc. (NUVB) Tops Q3 EPS by 1c, Beats on Revenue
-
Nuvation Bio begins phase 3 trial of safusidenib for brain cancer
-
Jefferies Starts Nuvation Bio Inc (NUVB) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
Nuvation Bio gets Japan approval for lung cancer drug IBTROZI
-
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
Nuvation Bio Inc (NUVB) PT Raised to $6 at Wedbush
-
Nuvation Bio Inc. (NUVB) Reports In-Line Q2 EPS
-
Citizens JMP Reiterates Market Outperform Rating on Nuvation Bio Inc (NUVB)
-
Nuvation Bio Inc (NUVB) PT Lowered to $6 at RBC Capital
-
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
Citizens JMP Reiterates Market Outperform Rating on Nuvation Bio Inc (NUVB)
-
Citizens JMP Reiterates Market Outperform Rating on Nuvation Bio Inc (NUVB)
-
Nuvation Bio (NUVB) Says FDA Approved IBTROZI
-
Nuvation Bio (NUVB) said granted FDA approval for Ibtrozi for non-small cell lung cancer
-
Citizens JMP Reiterates Market Outperform Rating on Nuvation Bio Inc (NUVB)
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Nuvation Bio Inc. (NUVB) Misses Q1 EPS by 1c
-
Citizens JMP Starts Nuvation Bio Inc (NUVB) at Market Outperform
-
Jones Trading Starts Nuvation Bio Inc (NUVB) at Buy
-
Nuvation Bio Inc (NUVB) PT Lowered to $10 at H.C. Wainwright
-
Nuvation Bio Inc. (NUVB) Misses Q4 EPS by 1c
-
Nuvation Bio (NUVB) Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
-
Nuvation Bio executive Jerry Wang to depart after key milestones
-
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
-
Nuvation Bio (NUVB) Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
Nuvation Bio (NUVB) Announces FDA Acceptance for Priority Review of New Drug Application for Taletrectinib
-
Clear Street Starts Nuvation Bio Inc (NUVB) at Buy
-
Nuvation Bio Inc. (NUVB) Misses Q3 EPS by 1c
-
Nuvation Bio (NUVB) Appoints Philippe Sauvage as CFO
-
Nuvation Bio Inc (NUVB) PT Lowered to $7 at H.C. Wainwright
-
Nuvation Bio Inc. (NUVB) Misses Q2 EPS by 183c

